Johns Hopkins examines the compounding problem in peptide therapies
The university piece focuses on risks and oversight gaps surrounding compounded peptide products.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 16 06:00 ETSource: Johns Hopkins University
The wire
- 01Johns Hopkins published an analysis titled 'The compounding problem of peptides.'
- 02Compounded peptides have drawn scrutiny as demand outpaces approved supply and regulatory clarity.
- 03Specific findings and policy recommendations were not detailed in the excerpt.
From the source
Read at news.google.comThe compounding problem of peptides